Idiopathic Pulmonary Fibrosis Treatment Market - Forecasts from 2019 to 2024

January 2019 | 95 pages | ID: I9E048E931CEN
Knowledge Sourcing Intelligence LLP

Abstracts

The global idiopathic pulmonary fibrosis treatment market is expected to reach US$4.020 billion by 2024 from US$2.090 billion in 2018, at a CAGR of 11.52%. Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive fibrosing interstitial pneumonia characterized by the formation of scar tissue within the lungs in the absence of any known cause. The scarring typically starts at the edges of the lungs and advances towards the center of the lungs. As the normal lung tissue is replaced by more heavily scarred lung tissue, which makes it difficult to breathe and deliver needed oxygen to the body. The disease initially manifests with symptoms of exercise-induced breathlessness and dry coughing. Diagnostic tests for IPF include chest imaging studies (X-Rays and CT scan), lung biopsy, pulmonary function tests, oxygen desaturation study and other tests such as autoantibody tests, full blood count, arterial blood gas etc. Currently there are two drugs approved for the treatment of IPF: Nintedanib and Pirfenidone. Both the drugs slow down the development of scar tissue in the lungs of people with IPF. Growth in prevalence of fibrotic disease coupled with the unavailability of proper treatment options will drive the market for the idiopathic pulmonary fibrosis treatment during the given time frame.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global idiopathic pulmonary fibrosis market value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global idiopathic pulmonary fibrosis market.

Major industry players profiled as part of the report are Boehringer Ingelheim, Hoffmann-La Roche, Prometic Life Sciences Inc., and Fibrogen Inc. among others.

Segmentation

By Treatment type
Medication
Lung Transplant
By Gender
Male
Female
By Age Group
50-70
71 and above
By Geography
North America
United States
Canada
South America
Brazil
Europe
United Kingdom
Germany
Middle East and Africa
Asia Pacific
China
Japan
India

Contents

1. INTRODUCTION

1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

2.1. Research Design
2.2. Secondary Sources
2.3. Validation

3. KEY FINDINGS OF THE STUDY

4. MARKET DYNAMICS

4.1. Market Segmentation
4.2. Drivers
4.3. Restraints
4.4. Opportunities
4.5. Porter’s Five Forces Analysis
  4.5.1. Bargaining Power of Suppliers
  4.5.2. Bargaining Power of Buyers
  4.5.3. Threat of New Entrants
  4.5.4. Threat of Substitutes
  4.5.5. Competitive Rivalry in the Industry
4.6. Product Pipeline
4.7. Epidemiology

5. IDIOPATHIC PULMONARY FIBROSIS (IPF) TREATMENT MARKET FORECAST BY TREATMENT TYPE

5.1. Medication
5.2. Lung Transplant

6. IDIOPATHIC PULMONARY FIBROSIS (IPF) TREATMENT MARKET FORECAST BY GENDER (US$ BILLION)

6.1. Male
6.2. Female

7. IDIOPATHIC PULMONARY FIBROSIS (IPF) TREATMENT MARKET FORECAST BY AGE GROUP (US$ BILLION)

7.1. 50-70
7.2. 71 and above

8. IDIOPATHIC PULMONARY FIBROSIS (IPF) TREATMENT MARKET FORECAST BY GEOGRAPHY (US$ BILLION)

8.1. North America
  8.1.1. The U.S
  8.1.2. Canada
8.2. South America
  8.2.1. Brazil
8.3. Europe
  8.3.1. U.K.
  8.3.2. France
  8.3.3. Germany
8.4. Middle East and Africa
8.5. Asia Pacific
  8.5.1. China
  8.5.2. Japan
  8.5.3. India

9. COMPETITIVE INTELLIGENCE

9.1. Competition and Offerings Analysis of Key Vendors
9.2. Strategies of Key Players
9.3. Recent Investments and Deals

10. COMPANY PROFILES

10.1. Boehringer Ingelheim
10.2. Hoffmann-La Roche
10.3. Lung Therapeutics
10.4. Fibrogen Inc.
10.5. Prometic Life Sciences Inc.
10.6. Samumed, LLC
10.7. ProterixBio, Inc
10.8. Galapagos NV
10.9. Celdara Medical
10.10. AdAlta Limited
List of Tables
List of Figures